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In mammals, biominerals consist of calcium and phosphate 
which form hydroxyapatite. Complex molecular and cellular 
mechanisms have evolved permitting crystallization of 
calcium and phosphate (i.e., forming hydroxyapatite) only 
at specific sites of the body. Pyrophosphate (PPi) is a central 
factor in the prevention of pathological calcium-phosphate 
precipitation in soft peripheral tissues [for a recent review 
see (1)].
Pseudoxanthoma elasticum (PXE, OMIM 264800) is 
a slowly progressing inherited calcification disease with 
clinical manifestations in the skin, eyes and in the tunica 
media of arterial blood vessels. The prevalence of PXE is 
estimated at 1:25,000–100,000. PXE severely affects the 
quality of life: almost all patients eventually develop eye 
lesions and a subset of patients suffers from cardiovascular 
problems [for a recent review see (2,3)]. Due to calcification 
of the Bruch’s membrane of the eye what is accompanied 
with angioid streaks and often results in neovascularization, 
the most severe clinical symptom in PXE is the loss 
of central vision in late-stage of the disease. The first 
symptoms affect the skin, where yellow papules appear on 
the neck. Later the skin looses elasticity and gets wrinkled. 
Mineralized lesions in small and medium-sized artery walls 
are typical and peripheral artery disease causing intermittent 
claudication is often reported by PXE patients. Mutations 
in ABCC6 cause pseudoxanthoma elasticum.
PXE is generally considered as a “metabolic disease”, 
this assumption is based on the following results: (I) the 
protein, ABCC6, is an organic anion transporter what is not 
expressed in the tissues of organs attacked by calcification, 
but it is highly expressed in the liver, and to a much lesser 
extent in the kidney and the intestines. This observation 
was the basis of the early hypothesis that an unknown 
metabolite (or its precursor) is transported from the liver 
into the circulation thus preventing connective tissue/soft 
tissue ectopic calcification; (II) experiments performed in 
the Uitto lab supported the above hypothesis: parabiotic 
connection of the circulation of Abcc6–/– and wt mice 
prevented calcification to a large extent in the KO animal (4). 
Transplantation of skin grafts between wt and KO mice 
resulted in prevention of calcification of the graft from the 
KO onto the wt, while the skin transplant from wt onto 
KO has been calcified (5); (III) metabolome screening by 
the van der Wetering laboratory provided evidence that 
ABCC6 is capable to transport (more accurately to facilitate 
the transport) of mono-, di- and trinucleotides, including 
ATP. The same lab showed that ATP is released from 
hepatocytes on an ABCC6-mediated manner in the liver 
microcirculation where it is promptly converted to AMP 
and PPi by the ectoenzyme ectonucleotide pyrophosphatase 
phosphodiesterase 1, ENPP1 (6,7). They also showed that 
the plasma level of PPi in PXE patients and in the Abcc6–/– 
mice is approximately 40% of the normal. A massive PPi 
efflux from the liver by perfusion was detected, the efflux 
was highly reduced when Abcc6–/– animals were studied. On 
the same line, lower PPi release from Abcc6–/– hepatocytes 
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kept in sandwich culture was shown when compared to the 
wild type. These findings led to the conclusion that the 
main source of circulating PPi is the liver. 
ABCC6 is a transmembrane transporter, and is localized 
to the sinusoidal side of hepatocytes (i.e., in the basolateral 
membrane compartment) (8,9). ENPP1 is also present in 
the liver as a membrane-attached protein. AMP, generated 
by ENPP1 is further cleaved to Pi and adenosine by the 
ecto 5’-nucleotidase, NT5E (CD73). Adenosine is a potent 
inhibitor of tissue non-specific alkaline phosphatase TNAP 
(encoded by ALPL). Reduction in adenosine level has been 
suggested to cause the calcification of large arteries (10) due 
to increased TNAP activity. TNAP hydrolyses PPi; this 
explains why NT5E-deficiency leads indirectly to reduction 
of PPi levels. Indeed, it was shown that mice lacking Nt5e 
have reduced plasma PPi due to the higher TNAP activity 
because of the lack of adenosine, leading to the degradation 
of extracellular PPi (11). 
Inactivating mutations in the genes encoding enzymes 
involved in PPi homeostasis result in rare hereditary 
calcification disorders: in addition to the ABCC6–
PXE relationship, mutations in ENPP1 are the genetic 
background of Generalized Arterial Calcification of Infancy 
(GACI, OMIM 208000), while Calcification of Joints and 
Arteries; CALJA, alternative name: Arterial Calcification 
due to CD73 Deficiency, ACDC (OMIM 211800) is caused 
by mutations in NT5E. The schematic representation of 
the above anti-calcification network is shown of Figure 1.
No specific treatment is available for halting of ectopic 
mineralization in PXE. However, in the treatment of ocular 
complications utilizing vascular endothelial growth factor 
antagonists has been proven to be a successful intervention 
which prevents neovascularization and generally helps to 
preserve vision (12). As the most severe complication of 
PXE is the loss of vision, this approach provides a great 
help for PXE patients.
The paper we discuss here brings two major messages: 
the first is related to the generally accepted “metabolic 
mechanism”, while the second is a novel idea for 
intervention of calcification in PXE, thus opening avenues 
for a new direction of therapy.
The authors carried out several knock-out experiments 
to demonstrate the role of Abcc6 ,  Enpp1  and Nt5e 
genes in soft tissue calcification. They concluded from 
these experiments that all three genes participate in 
the inhibition of ectopic calcification. They suggest 
a mechanism according to which ABCC6 and CD73 
cooperate downstream of ENPP1 to inhibit TNAP 
expression thus providing sufficient PPi levels to 
circumvent soft tissue calcification. As it is written in the 
paper: “we provide both genetic and biochemical studies that 
suggest a role for ABCC6 distal to the degradation of ATP to 
AMP and PPi by ENPP1”. However, to fully understand 
the molecular mechanism of the observed phenomenon, 
further experiments should be carried out and they don’t 
exclude the validity of the original model either. This led 
us to propose a mechanistic model what we graphically 
summarize on Figure 1, and indicate the suggested 
hypothetical extensions of the original model.
By performing partial knock-out experiments Ziegler 
and coworkers also showed, that several tissues participate 
in the Abcc6 dependent ectopic calcification. Indeed, they 
observe that when Abcc6 is deleted only from the major 
site of expression (from the liver, under otherwise wild-
type conditions), the ectopic calcification phenotype is 
much less prominent although still present compared 
to complete Abcc6 knock out animal (i.e., in the case of 
Abcc6–/–). This strongly suggests that other tissues, in 
Figure 1 Schematic representation of the anti-calcification 
network involving ABCC6. The following metabolic steps stat with 
ATP release from hepatocytes mediated by ABCC6; the conversion 
of ATP to AMP and pyrophosphate (PPi) by the enzyme ENPP1; 
the hydrolysis of AMP to adenosine and phosphate by NT5E 
and the hydrolytic destruction of PPi by TNAP. Adenosine 
generated by NT5E inhibits TNAP activity thus regulating PPi 
levels. The Ziegler paper suggests alternative elements to the 
currently established model mechanism that are also shown in 
the figure. The therapeutic approach described in the paper (i.e., 
pharmacological inhibition of TNAP) is also indicated.
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which Abcc6 is expressed to a much lower extent than 
in the liver, e.g., the kidney or the intestines, also play 
role in the pathomechanism of soft tissue calcification 
at least in conditions when ABCC6 is absent from the 
liver. In such a case these or other tissues might partially 
rescue the phenotype either by upregulating their own 
Abcc6 expression or by other, unknown mechanisms. The 
local events described elegantly in the Ziegler paper are 
important and complement well the primary systemic 
events associated to the liver. This may be supported by the 
fact that PPi supplementation therapies in Abcc6–/– mice 
or restoring ABCC6 activity exclusively in the liver led to 
60–80% inhibition of calcification in the same mouse model 
Ziegler et al. used (13-16).
The paper convincingly raised the therapeutic potential 
of a TNAP inhibitor (SBI-425) in the Abcc6–/– mouse 
model. This is a very important discovery. They state that 
“although TNAP inhibition does not reverse existing calcification 
in this experimental context, it can prevent progression of the 
phenotype...”. This result is in line with other therapeutic 
options suggested very recently, as we discuss in detail later 
in the present editorial. The above result enforces that 
TNAP is an important calcification mediator and raises 
the possibility that in other connective tissue calcification 
disorders (e.g., in CD73 deficiency) it may be considered 
as a therapeutic target. Ziegler and colleagues found that 
plasma PPi level remained unchanged (i.e., did not increase) 
upon SBI-425 treatment although the plasma TNAP 
activity was decreased. This is somewhat surprising in the 
light of previous results demonstrating significantly reduced 
PPi concentration in the plasma of Nt5e–/– mice (11). As 
we discussed above, the lack of NT5E leads to higher 
TNAP activity thus resulting higher rate of PPi hydrolysis 
(PPi elimination). One would expect that inhibiting PPi 
hydrolytic activity of TNAP should increase plasma PPi 
concentration. However, Ziegler et al. found no such 
increase. This apparent discrepancy requires further studies 
to be resolved.
In the current year there was a rich “harvest” of 
preclinical results toward potential systemic intervention 
(i.e., not only for the eye symptoms) in PXE. Each of them 
based on the normalization of PPi level—like in the paper 
we discuss in which inhibition of an enzyme (TNAP), which 
catalyses PPi hydrolysis is the basis of the therapeutical 
suggestions.
We list here those preclinical studies, which used in vivo 
approaches (i.e., Abcc6–/– mice) and reported successful 
inhibition of calcification, on a similar manner as the 
Ziegler paper. 
The Le Saux group demonstrated that a single daily 
injection of PPi to Abcc6–/– mice over several months 
prevented the development of spontaneous calcification (14). 
This raises the possibility that daily one transient increase 
of plasma PPi level may have preventive effect. However, 
due to the necessity to treat patients life-long, oral 
administration of PPi would be the preferential treatment. 
As phosphatases are abundantly present in the gut (17) 
it has been always claimed that orally administered PPi 
cannot appear in the circulation (i.e., its bioavailability 
is practically zero) and therefore it is not effective in 
inhibiting connective tissue calcification (1). In spite of the 
general assumption, we demonstrated significant inhibition 
of calcification in two different well-characterized mouse 
models of ectopic calcification disorders, PXE and GACI, 
when the animals were treated with PPi orally. The 
observed transient elevation of PPi in plasma found in 
healthy human volunteers indicates that in PXE patients 
PPi levels may be transiently raised to the physiological 
level with the dosage used. As PPi is considered to be non-
toxic this option may have great clinical potentials. 
Most mutations in ABCC6 are missense, and many 
of these mutations preserve transport activity but cause 
intracellular retention (18,19). This year it has been 
published that chemical chaperone 4-phenylbutyrate (4-
PBA) not only promotes the maturation of missense 
ABCC6 mutants to the plasma membrane but restores the 
physiological function of selected ABCC6 missense mutants 
expressed in the liver of living Abcc6–/– mice resulting 
in calcification inhibition (13). This study identifies the 
treatments based on the repurposing use of 4-PBA as a 
promising strategy for allele-specific therapy in PXE. 
The remarkable finding of Ziegler et al., that inhibition 
of TNAP is also effective in attenuating calcification 
in the animal model of PXE is a promising alternative 
approach. The above listed options fuel the optimism that 
treatments targeting the calcification symptoms of PXE are 
foreseeable. It is also possible that combination of the above 
interventions will be the most effective.
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